TREMFYA Approved by U.S. FDA as the First Selective Interleukin Inhibitor for Active Psoriatic Arthritis
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. FDA has approved TREMFYA for adult patients with active psoriatic arthritis (PsA),...
Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab
Catalent and Humanigen, Inc. announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigen’s proprietary...
Thermo Fisher Scientific and First Genetics JCS Partner to Develop Next-Generation Sequencing-Based Diagnostics in Russia
Thermo Fisher Scientific and First Genetics JCS, a manufacturer of diagnostic equipment and IVD kits intended to advance molecular genetic technologies into clinical practice,...
Glenmark Becomes the First Pharmaceutical Company in India to Receive Regulatory Approval for Oral Antiviral Favipiravir, for the Treatment of Mild to Moderate COVID-19
In a landmark development for COVID-19 patients in India, Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced the launch of antiviral drug Favipiravir...
Gilead announces results from Phase 3 Trial of remdesivir in patients with moderate COVID-19
Gilead Sciences, Inc. announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label study evaluated 5-day...
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre
Oxford Biomedica plc, a leading gene and cell therapy group, announced that it has signed a Collaboration Agreement with the Vaccines Manufacturing and Innovation...
Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO in Multiple Myeloma
Takeda Pharmaceutical Company Limited announced it will orally present the results of two studies at the 25th Congress of the European Hematology Association (EHA)....
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...